| Revenue growth | FY26 Consolidated: ₹332.60 Cr, Standalone: ₹292.14 Cr. |
|---|---|
| Margins | Consolidated PAT margin significantly improved to ₹57.48 Cr in FY26. |
| Demand visibility | Strong via WOAH vaccine bank and African LSD vaccine leadership. |
Growth
Consolidated revenue grew to ₹332.60 Cr in FY26 from ₹311.10 Cr in FY25; PAT rose to ₹57.48 Cr.
Outlook
Expanding Petcare division in India; ongoing R&D for new vaccine ranges; scaling ruminant vaccine accessibility in Africa.
Risks
Expansion risks in African markets (Kenya, Nigeria, Tanzania) and reliance on global vaccine bank tenders.
Earnings Call filed with BSE, NSE: HESTERBIO. Summary written with AI assistance from the document.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,165.30
- Market cap
- ₹1,842 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.5×Sector 47.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences Annual General Meeting
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Other Announcement
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.